Early overactivation of non-muscle myosin II during adaptation to combined BRAF and MEK inhibitors in dedifferentiating cutaneous melanomas
Authors:
- Andrea Garcia-PerezAGAndrea Garcia-Perez
- Lucía Sanchez-GarciaLSLucía Sanchez-Garcia
- Marta Duran-RenieblasMDMarta Duran-Renieblas
- Federica SellaFSFederica Sella
- Silvia Novo-AcedoSNSilvia Novo-Acedo
- Angel Delgado-LopezADAngel Delgado-Lopez
- Adrian BarrenoABAdrian Barreno
- Judith GraciaJGJudith Gracia
- Christopher RiosCRChristopher Rios
- Erica J. YoungEYErica J. Young
- Laszlo RadnaiLRLaszlo Radnai
- Clara Diaz-UtrillaCDClara Diaz-Utrilla
Preprint
Abstract
Cutaneous melanoma is a very aggressive type of skin cancer with remarkable phenotypic plasticity that contributes to adaptation and resistance to targeted therapies against the MAPK pathway. Previous research described that non-muscle myosin II (NMII) of the actomyosin cytoskeleton, which is essential for cell migration and metastasis, is overactivated in BRAF inhibitor-resistant melanomas. Since the combination of BRAF and MEK inhibitors (BMi) is the current standard of care, we investigated if and how NMII activity is regulated during adaptation to BMi. Here, we find that most dedifferentiating BMi-resistant melanomas overactivate NMII compared to their parental counterparts. NMII activity generally increases during the first 2 weeks of BMi treatment, and it is followed by elevated total NMII levels due partly to transcriptional modulation. Although ERK activity rebounds with similar kinetics, NMII overactivation is not prevented by ERK inhibition but by blockade of ROCK. In melanomas that hyperdifferentiate during adaptation to BMi, NMII activity is not increased upon BMi treatment due, in part, to MITF. We also find that co-targeting NMII along BMi in some melanomas reduces survival of drug-tolerant persister cells, which would delay the development of resistance. Therefore, our study identifies elevated NMII activity as a potential marker of adaptation to MAPK in some melanoma subpopulations, and also provide an approach to delay the emergence of resistance to MAPK-targeted therapy.Keywords
Funding Information
- Instituto de Salud Carlos III (PI18/00573, PI21/00294, PI24/1433)
This publication has 76 references indexed in Scilit:
- FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanomaCancer Cell, 2025
- Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanomaCancer Cell, 2021
- Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy ResistanceCancer Cell, 2020
- A Convergence-Based Framework for Cancer Drug ResistanceCancer Cell, 2018
- Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative StressCancer Cell, 2018
- Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma TherapyCancer Cell, 2016
- Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi ResistanceCell, 2015
- Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK SignalingCancer Cell, 2015
- Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not EncouragedCancer Cell, 2014
- Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E MelanomasCancer Cell, 2012